Rapamycin, a key modulator of the mammalian Target of Rapamycin (mTOR) pathway has shown neuroprotection properties in several neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, Huntington's disease and spinocerebellar ataxia type 3 [71, 72, 85]. Here, MTOR is linked to Spinocerebellar ataxia type 3.